The PAC-MANN test was able to differentiate — 98% of the time — between the blood of someone with pancreatic cancer and the blood of someone who doesn’t have the disease. When used alongside the existing CA 19-9 test, it was able to diagnose early-stage pancreatic cancer with 85% accuracy.

A new assay rapidly detected pancreatic ductal adenocarcinoma and differentiated it from noncancer pancreatic diseases by measuring cancer-associated protease activity in a small amount of blood.

Paired with an existing test, this could become a life-saving diagnostic tool for people with a notoriously deadly form of cancer.

Scientists at Oregon Health and Science University (OHSU) have developed a new blood test for pancreatic cancer, one of the most deadly forms of the disease. Tests showed up to 85% accuracy in detection,